Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China.

ABSTRACT:

Background

The LITESPARK-005 trial demonstrated the efficacy and safety of belzutifan in patients with previously treated clear cell renal cell carcinoma (ccRCC). This study aims to evaluate the cost-effectiveness of belzutifan compared to everolimus in treating patients with advanced ccRCC who have received at least one systemic therapy from the perspective of the Chinese healthcare system and the US payers.

Objectives

To provide previously treated ccRCC patients with the option of belzutifan and to offer recommendations regarding in China.

Design

The cost-effectiveness analysis.

Methods

A partitioned survival model was constructed based on data from the LITESPARK-005 trial. Patients transitioned through three mutually exclusive health states: progression-free

SUBMITTER: Ding B 

PROVIDER: S-EPMC12491818 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature